The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
|
10. A process for preparing a compound of formula (I) which comprises:
(a) Bisacylating a diamine of formula (II): HN(R2)--Y--(R2)NH formula (II) wherein R2 and Y are as defined in formula (I) or Y may additionally be protected by a suitable protecting group; with a compound of formula (IV): R1 --CO2 H formula (IV) wherein R1 is as defined in formula (I), using a suitable activating agent in a suitable polar aprotic solvent, followed by removal of any protecting groups and, if desired, by salt formation; or alternately by: (b) transforming the acid of formula (IV) to an acid halide: R1 COX' wherein R1 is as defined in formula (I), and X' is a halogen atom, that is reacted with the diamine of formula (II) HN(R2)--Y--(R2)NH formula (II) wherein R2 and Y are as defined in formula (I) or Y may additionally be protected by a suitable protecting group; in the presence of a suitable base, in a suitable solvent, followed by removal of any protecting groups and, if desired, by salt formation. 1. A compound of formula (I) ##STR15## wherein: R1 is independently a 4-10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two C1-4 alkyl, F, Cl, Br, I, C1-4 alkoxy, (CH2)m R6, oxo, oxime, O-C1-4 alkyloxime, hydroxy, N(R5)2, acylamino or aminoacyl groups, 8, 9, 10 membered moncyclic ring sytems being excluded;
R2 is independently hydrogen, C1-4 alkylC(O)R6, C1-4 alkyl or R2 is benzyl which is optionally substituted by one or two C1-4 alkyl, C1-4 alkoxy, F, Cl, I, Br, OH, or N(R5)2 ; Y is (CH2)n, in which at least one carbon is gem-substituted by R3 and R4 ; R3 and R4 are independently C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl; all of which may be substituted by one or two C1-4 alkyl, OH, F, Cl, Br, I, N(R5)2, (R5)2 NC(O)--, --(CH2)m R6, --(CH2)m R5, --(CH)2)m COR6, or --(CH2)m C(O)R5 ; or R3 and R4 are F, Cl, or Br; or R3 and R4 may together form a cyclic or heterocyclic ring of formula (Ia): ##STR16## in which p and q are independently an integer from 0 to 3; X is O, S, CH2 or N(R5); R5 is independently hydrogen, C1-4 alkyl, or benzyl; R6 is independently OR5, N(R5)2 or SR5 ; and n is an integer from 3 to 8; m is an integer from 0 to 4; or a pharmaceutical acceptable salt thereof; provided: p and q are not both 0; and when R3 and R4 are F, Cl or Br, they are not on a carbon adjacent to the nitrogen.
2. A compound of
3. A compound of
4. A compound of
3,3-Bis(picolinamidomethyl)oxetane; 4,4-Bis(picolinamidomethyl)tetrahydro-4H-pyran; 2,2- Bis (picolinoylamidomethyl) 1,3 propanediol; N,N'-Bis(picolinoyl)-1,5-diamino-2,2-dimethylpropane; N,N'-Bis(picolinoyl)-1,5-diamino-3,3-dimethylpentane; and 1,1-Bis(picolinamidomethyl)cyclopropane. 6. A pharmaceutical composition comprising a compound of formula (I) of
7. A method of preventing or treating viral, fungal or bacterial infections which comprises administering to an animal in need thereof, an effective amount of a compound of formula I of
8. A method of stimulating mylopoiesis in an animal in need thereof by administering a compound of
9. A method of treating or preventing sepsis in an animal in need thereof by administering a compound of
|
|||||||||||||||||||||||||||||||||||||||||
This application is a 371 of PCT/US96/18126 Nov. 12, 1996.
The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
The hematopoietic system is a life-long cell renewal process whereby a defined stem cell population gives rise to a larger population of mature, differentiated blood cells (Dexter T M. Stem cells in normal growth and disease. Br Med J 1987; 195:1192-1194) of at least nine different cell lineages (erythrocytes, platelets, eosinophils, basophils, neutrophils, monocytes/macrophages, osteoclasts, and lymphocytes) (Metcalf D. The Molecular Control of Blood Cells. 1988; Harvard University Press, Cambridge, Mass.). Stem cells are also ultimately responsible for regenerating bone marrow following treatment with cytotoxic agents or following bone marrow transplantation.
The major dose-limiting toxicities of most standard anti-neoplastic drugs are related to bone marrow suppression, which if severe and prolonged, can give rise to life-threatening infectious and hemorrhagic complications. Myelosuppression is predictable and has been reported to be dose-limiting in greater than 50% of single-agent Phase I trials cytotoxic compounds (Merrouche Y, Catimel G, Clavel M., "Hematopoietic growth factors and chemoprotectants; should we move toward a two-step process for phase I clinical trials in oncology?" Ann Oncol 1993; 4:471-474). The risk of infection is directly related to the degree of myelosuppression as measured by the severity and duration of neutropenia (Brody G P, Buckley M, Sathe Y S, Freireich E J. "Quantitative relationship between circulating leukocytes and infections with acute leukemia." Ann In Med 1965; 64:328-334).
The control of hematopoiesis involves the interplay of a variety of cytokines and growth factors during various stages of the hematopoietic cascade, including early pluripotent stem cells and mature circulating effector cells. These regulatory molecules include granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), and a variety of interleukins which have overlapping, additive and synergistic actions which play major roles in host defense. Mechanistically, this is accomplished by enhancing the production of granulocytes and macrophages, as well as by the activation of effector cell functions (Moore M A S. Hemopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surveys 1990; 9:7-80). These coordinated activities support optimal host defences which are necessary for fighting bacterial, viral and fungal infections.
Strategies to prevent or reduce the severity of neutropenia and myelotoxicity include the use of hematopoietic growth factors and/or other hematopoietic cytokines. Such treatments are becoming common practice, in that they offer the potential of increased doses of cytotoxic agents that may improve the therapeutic efficacy of antineoplastic agents, and reduce the morbidity associated with their use (Steward W P. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342:153-157). Clinical studies have demonstrated the G-, GM- and/or M-CSF may reduce the duration of neutropenia, accelerate myeloid recovery, and reduce neutropenia-associated infections and other infectious complications in patients with malignancies who are receiving cytotoxic chemotherapy or in high infectious-risk patients following bone marrow transplantation (Steward W P. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342:153-157 and Munn D H, Cheung N K V. Preclinical and clinical studies of macrophage colony-stimulating factor. Semin Oncol 1992; 19:395-407).
Synthetic peptides have been reported to induce the synthesis and release of hematoporetic mediators, including m-CSF from bone marrow stromal elements see U.S. patent application 08/001,905.
We have now found certain novel non-peptide compounds which have a stimulative effect on myelopoietic cells. They are useful in stimulating myelopoiesis in patients suffering from reduced myelopoietic activity, including bone marrow damage, agranulocytosis and aplastic anemia including patients having depressed bone marrow function due to immunosuppressive treatment to suppress tissue reactions i.e. in bone marrow transplant surgery. They may also be used to promote more rapid regeneration of bone marrow after cytostatic chemotherapy and radiation therapy for neoplastic and viral diseases. They may be of particular value where patients have serious infections due to a lack of immune response following bone marrow failure. They are also useful in the treatment and prevention of viral, fungal and bacterial disease.
This invention comprises compounds, hereinafter represented as Formula (I), which have hemoregulatory activities and can be used to stimulate hematopoiesis and in the prevention and treatment of bacterial, viral and fungal diseases.
These compounds are useful in the restoration of leukocytes in patients with lowered cell counts resulting from a variety of clinical situations, such as surgically induced myelosuppression, AIDS, ARDS, congenital myelodysplacia, bone marrow and organ transplants; in the protection of patients with leukopenia from infection; in the treatment of severely burned patients and in the amelioration of the myelosuppression observed with some cell-cycle specific antiviral agents and in the treatment of infections in patients who have had bone marrow transplants, especially those with graft versus host disease, in the treatment of tuberculosis and in the treatment of fevers of unknown origin in humans and animals. The compounds are also useful in the treatment and prevention of viral, fungal and bacterial infectious diseases, particularly Candidiasis and Herpes in both immunosuppressed and "normal" subjects. They are useful in the treatment of sepsis caused by gram negative and gram positive organisms.
These compounds may also be used in combination with the myelosuppresive agents of co-pending U.S. application No. 07/799,465 and U.S. Pat. No. 4,499,081, incorporated by reference herein, to provide alternating peaks of high and low activity in the bone marrow cells, thus augmenting the natural circadian rhythm of hematopoiesis. In this way, cytostatic therapy can be given at periods of low bone marrow activity, thus reducing the risk of bone marrow damage, while regeneration will be promoted by the succeeding peak of activity. This invention is also a pharmaceutical composition, which comprises a compound of Formula (II) and a pharmaceutically acceptable carrier.
This invention further constitutes a method for stimulating the myelopoietic system of an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
This invention also constitutes a method for preventing and treating viral, fungal and bacterial infections in immunosuppressed and normal animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
This invention further constitutes a method for preventing and treating sepsis caused by gram positive and gram negative organisms in animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
The compounds of the invention are represented by structural Formula (I) ##STR1## wherein: R1 is independently a 4-10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two C1-4 alkyl, F, Cl, Br, I, C1-4 alkoxy, (CH2)m R6, oxo, oxime, O-C1-4 alkyloxime, hydroxy, N(R5)2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded;
R2 is independently hydrogen, C1-4 alkylC(O)R6, C1-4 alkyl or R2 is benzyl which is optionally substituted by one or two C1-4 alkyl, C1-4 alkoxy, F, Cl, I, Br, OH, or N(R5)2 ;
Y is (CH2)n, in which at least one carbon is gem-substituted by R3 and R4 ;
R3 and R4 are independently C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl; all of which may be substituted by one or two C1-4 alkyl, OH, F, Cl, Br, I, N(R5)2, (R5)2 NC(O)--, --(CH2)m R6, --(CH2)m R5, --(CH)2)m COR6, or --(CH2)m C(O)R5 ; or R3 and R4 are F, Cl, or Br; or R3 and R4 may together form a cyclic or heterocyclic ring of Formula (Ia): ##STR2## in which p and q are independently an integer from 0 to3; X is O, S, CH2 or N(R5);
R5 is independently hydrogen, C1-4 alkyl, or benzyl;
R6 is independently OR5, N(R5)2 or SR5 ; and
n is an integer from 3 to 8;
m is an integer from 0 to 4;
or a pharmaceutical acceptable salt thereof; provided:
p and q are not both 0; and
when R3 and R4 are F, Cl or Br, they are not on a carbon adjacent to the nitrogen.
C1-4 alkyl groups may be straight or branched.
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All these compounds and diastereomers are contemplated to be within the scope of the present invention.
R1 in the above Formula (I) denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, isoindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl, 2-pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, piperidyl, tetrazolyl, quinuclidinyl, azetidinyl, or purinyl;
Preferred compounds are those wherein R1 is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl, azetidinyl, or pyrrolidinyl; n is 3-5; R3 and R4 are C1-4 alkyl, substituted by C1-4 alkyl, OH, N(R5)1-2, --(CH2)m R6, or --(CH2)m C(O)R5 ; or R3 and R4 may together form a cyclic or heterocyclic ring of Formula (Ia) wherein X is O, S, or CH2 ; and p and q are 1-3; R5 is hydrogen or C1-4 alkyl; and R6 is OR5 or N(R5)1-2.
More preferred compounds are those wherein R1 is 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl, 2-pyrrolidon-5-yl, or 2-pyrrolidinyl; n is 3 or 5; R3 and R4 are C1-2 alkyl, substituted by C1-2 alkyl, OH, N(R5)2, or --(CH2)m R6 ; or R3 and R4 may together form a heterocyclic ring of Formula (Ia) wherein X is O; and p and q are 1 or 2; R5 is hydrogen or C1-4 alkyl; and R6 is OR5, or N(R5)1-2.
Preferred compounds are:
3,3-Bis(picolinamidomethyl)oxetane,;
4,4-Bis(picolinamidomethyl)tetrahydro-4H-pyran;
2,2-Bis(picolinoylamidomethyl) 1,3 propanediol;
N,N'-Bis(picolinoyl)-1,5-diamino-2,2-dimethylpropane;
N,N'-Bis(picolinoyl)-1,5-diamino-3,3-dimethylpentane; and
1,1-Bis(picolinamidomethyl)cyclopropane.
The invention also is a pharmaceutical composition comprising as an active ingredient of one or more compounds of Formula (I) in association with a pharmaceutical carrier or excipient.
The invention is also a method of stimulating myelopoiesis in an animal, including humans, in need thereof by administering an effective amount of a compound of Formula I.
The invention is further a method of preventing or treating viral, fungal or bacterial infections comprising administering to an animal, including humans, in need thereof, an effective amount of a compound of Formula (I).
Compounds of Formula (I) ##STR3## wherein R1, R2 and Y are as defined for Formula(I), are prepared as outlined in Scheme I. ##STR4## by reacting a suitable activated acid (R1 --COOH) with a suitable diamine (R2 --NH--Y--NH--R2) or its salt form in a suitable solvent such as methylene chloride (CH2 Cl2) or N,N-dimethylformamide (DMF) to give the final product. The carboxylic acid is activated with a suitable activating agent such as 1,3-dicylohexylcarbodiimide (DCC), benzotriazol-1-yloxy-tris(dimethyl-amino)phosphonium hexafluorophophate (BOP reagent), or 2-(1,H-benzotriazol-1-yl)-1,1,3,3, tetramethyluronium tetrafluoroborate (TBTU reagent). The reaction is catalyzed by a suitable catalyst such as 1-hydroxybenzotriazole hydrate (HOBt) or 4-dimethylaminopyridine (DMAP). If the amine is in its salt form, it must be neutralized by a suitable base such as triethylamine, Hunig's base or N-methyl morpholine.
Alternatively, the acid is transformed to an acid halide that is reacted with an amine in the presence of a suitable base such as triethylamine, Hunig's base, or N-methyl morpholine, in a suitable solvent such as CH2 Cl2, Benzene, or DMF to form the compound of Formula (I).
The amines of formula (II) (R2 --NH--Y--NH--R2) may be obtained as shown in Scheme II ##STR5## by reacting an appropriately protected diamine (NH2 --Y--NH2) with an alkyl halide in the presence of base such as NaH. The reaction can be carried out in dioxane or DMF. The most commonly used protecting groups are t-butyloxycarbonyl (t-Boc-) or carbobenzyloxy (Z-). The methods of removing these protecting groups are well known in the art.
The amines of Formula (II) wherein R2 is C2-4 alkyl or C2-4 alkylC(O)R6 may also be prepared as shown in Scheme (III) ##STR6## by reacting amines of formula III or IV with an aldehyde (R2--CHO) and a suitable reducing agent such as Sodium cyanoborohydride in a suitable solvent such as methanol.
The amines of Formula III (NH2 --Y--NH2) can be obtained commercially or are prepared by reacting a suitable bisalkylhalide with ammonia.
The amines of Formula III or IV may also be prepared by reducing bisalkylnitiles or bisalkylazides as shown in Scheme IV ##STR7##
The compounds of Formula VI are prepared as shown in Scheme V ##STR8## by sequentially reacting compounds of Formula V with an aqueous acid and aqueous base to give the desired compounds.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
The compositions according to the invention may be presented for example, in a form suitable for oral, nasal, parenteral or rectal administration.
As used herein, the term "pharmaceutical" includes veterinary applications of the invention. These compounds may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such a glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule. Organ specific carrier systems may also be used.
Alternately pharmaceutical compositions of the compounds of this invention, or derivatives thereof, may be formulated as solutions of lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration and contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
For rectal administration, a pulverized powder of the compounds of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository. The pulverized powders may also be compounded with an oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propellant or provided with means for manual compression.
Dosage units containing the compounds of this invention preferably contain 0.05-50 mg, for example 0.05-5 mg of the compound of Formula (I) and (II) or salt thereof.
According to a still further feature of the present invention there is provided a method of stimulation of myelopoiesis which comprises administering an effective amount of a pharmaceutical composition of Formula (II) as hereinbefore defined to a subject.
No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by the following tests.
Induction of Hematopoietic Synergistic Activity in Stromal Cells
The murine bone marrow derived stromal cell line, C6.4 is grown in 12 well plates in RPMI 1640 with 10% FBS. Upon reaching confluence, the C6.4 cells are washed and the media exchanged with fresh RPMI 1640 without FBS. Confluent cell layers of murine C6.4 cells are treated with compound. Cell-free supernatants are collected 18 hours later. Supernatants are fractionated with a Centricon-30 molecular weight cut-off membrane. C6.4 cell hematopoietic synergistic factor (HSF) activity is measured in a murine CFU-C assay.
CFU-C Assay
Bone marrow cells are obtained from C57B 1/6 female mice and suspended in RPMI 1640 with 10% FBS. Bone marrow cells (7.5E+4 cells/mL) are cultured with sub optimal levels of CFU plus dilutions of test C6.4 cell 30K-E supernatants from above in a standard murine soft agar CFU-C assay. Cell aggregates >50 cells are counted as colonies. The number of agar colonies counted is proportional to the amount of HSF present within the C6.4 bone marrow stromal line supernatant.
Effector Cell Function Assay
Female C57B1 mice are administered test compound IP or PO daily for 8 days. Resident peritoneal exudate cells (PEC) utilized ex vivo from treated or untreated mice are harvested with cold calcium and magnesium-free DPBS supplemented with heparin and antibiotics within 2-4 hours following the last injection. Adherent PEM populations are prepared by incubating standardized PEC suspensions in microtiter dishes for 2 hours at 37°C (5% CO2) and removing nonadherent cells by washing the wells with warm buffer.
The superoxide dismutase-inhibitable (SOD) superoxide released by effector cells in response to a in vitro stimulation by phorbol myristate acetate (PMA) (100-200 nM) or pre-opsonized (autologous sera) live C. albicans (E:T=1:10) are quantitated in a microtiter ferricytochrome c reduction assay. The assay is performed in the presence of 1% gelatin/HBSS and 80 uM ferricytochrome c in a total volume of 200 uL/well. The nmoles of cytochrome c reduced/well is calculated from spectrophotometric readings (550 nm) taken following a 1 hour incubation at 37°C (5% CO2). The amount of SOD-inhibitable cytochrome c reduced is determined by the inclusion of wells containing SOD (200 U/well). Baseline superoxide release is determined in the absence of stimuli. Experimental data are expressed as a percentage of the control group.
The following examples are illustrative and are not limiting of the compounds of this invention.
All temperatures are given in Centigrade.
PAC 3,3-Bis(picolinamidomethyl)oxetane ##STR9##To a solution of 3,3-bisaminomethyloxetane dihydrobromide (0.05 g, 0.18 mmol) in DMF (3 mL) was added picolinic acid (0.07 g, 0.56 mmol), BOP reagent (0.24 g, 0.54 mmol), HOBt hydrate (0.07 g, 0.52 mmol) and iPr2 NEt (0.16 mL, 0.92 mmol). After 24 h, the reaction was quenched by pouring into 50% brine (10 mL) and extracting with EtOAc (3×15 mL). The combined organic extracts were dried over Na2 SO4 and concentrated to give a yellow oil (0.82 g). Flash chromatography (gradient 50% EtOAc/hexane to 100% EtOAc, silica gel) gave 0.02 g, (34%) of the above named product as a white solid. 1 H NMR (CDCl3, 250 MHz) δ8.82 (t, 2H, J=7 Hz), 8.61 (m, 2H), 8.23 (d,d, 2H, J=7.7, 1 Hz), 7.87 (d,t, 2H, J=7.7, 1.6 Hz), 7.45 (m, 2H), 4.59 (s, 4H), 3.87 (d, 4H, J=7Hz); MS (ES+) m/e 327.4 [M+H+ ].
PAC 2,2-Bis(picolinoylamidomethyl) 1,3 propanediol ##STR10## 3,3-Bis(picolinamidomethyl)oxetane (example 1) (25.6 mg, 0.078 mmol) was dissolved in 8 mL of 0.1 N HCl (aqueous) and stirred at room temperature for 18 h. The reaction was made basic (pH∼8) with 5% NaHCO3 (aqueous) and evaporated to dryness. The residue was taken into 10% MeOH/CHCl3, filtered and evaporated and the resulting material purified by flash chromatography (silica gel, 3×20 cm, 2% MeOH/CHCl3) to give two fractions. The first fraction contained 5 mg (0.015 mmol, 19%) of recovered starting material. MSES m/e 327 (M+H)+. The second fraction contained 19.3 mg (0.056 mmol, 72%) of the above named product. 1 H NMR (CDCl3, 250 MHz) δ8.77 (t, 2H, J=7Hz), 8.61 (m, 2H), 8.21 (d,d, 2H, J=7.8, 1 Hz), 7.88 (t,d, 2H, J=7.8, 1.7 Hz), 7.47 (m, 2H), 4.44 (t, 1H, J=7Hz), 3.48 (d, 4H, J=7Hz), 3.37 (d, 4H, J=7Hz); MS(ES+) m/e 345 [M+H]+. PAC 4,4-Bis(picolinamidomethyl)tetrahydro-4H-pyran ##STR11##To a stirred mixture of tetrahydro-4H-pyran-4,4-dicarbonitrile (0.33g, 0.002mole) in MeOH (10 ml) and 2N NaOH (9 ml) at 0° was added in portions, aluminum-nickel catalyst (0.59g, 0.01 mole). The reaction mixture was refluxed for 4 hours. The cooled mixture was adjusted to pH2 by dropwise addition of concentrated HCl. The mixture was then concentrated under reduced pressure at 40° to give an off-white solid.
To a solution of picolinic acid (0.59g, 0.0048mole) in benzene (25ml) and one drop of DMF was added under argon, oxalyl chloride (0.64g, 0.0048mole). The reaction was stirred at room temperature for 3 hours and then cooled to 0°. To this was added in one portion a suspension of the diamino-tetrahydropyran dihydrochloride salt of (0.35g, 0.0016mole) in chloroform (5 ml) containing diisopropylethylamine (2.06g, 0.016mole). The reaction was stirred under argon at room temperature for 2 hours. The mixture was poured out into 50ml of brine and extracted twice with EtOAc. The EtOAc extracts were dried(Na2 SO4), filtered and concentrated at 40° to a brown oil. The oil was flash chromatagraphed on silica gel eluting with EtOAc to yield 22.5mg of the above named product as a colorless oil.
1 H NMR(CDCl3)δ: 8.9(broad t, 2H), 8.6(m, 2H), 8.3(m, 2H), 7.8(m, 2H), 7.5(m, 2H), 3.9(t, 4H), 3.5(d, 4H), 1.6(t, 4H); MS (ES+) m/e 355 [M+H]+ ; 377 [M+H+Na]+.
PAC 1,1-Bis(picolinamidoethyl)cyclopropane ##STR12##In a manner analogous to that of Example 3, 1,1-diaminomethyl-cycopropane (0.53 g, 3.09 mmol), picolinic acid (1.14 g, 9.26 mmol), BOP reagent (4.10 g, 9.26 mmol), HOBt hydrate (1.25 g, 9.25 mmol) and Et3 N (2.60 mL, 18.6 mmol) gave 0.83 g (87%) of the above named product as a white foam. MS (ES+) m/e 311.4 [M+H+ ].
PAC N,N'-Bis(picolinoyl)-1,5-diamino-3,3-dimethylpentane ##STR13##In a manner analogous to that of Example 1, 3,3-dimethyl-1,5-diaminopentane (0.22 g, 1.70 mmol), picolinic acid (0.46 g, 3.74 mmol), BOP reagent (1.65 g, 3.74 mmol), HOBt hydrate (0.50 g, 3.74 mmol), and iPr2 NEt (2.96 mL, 17.0 mmol) gave a yellow oil. Trituration from hot EtOAc gave 0.24 g (42%) of the above named product as white crystals. MS(ES+) m/e 341.0 [M+H+ ].
PAC N,N'-Bis(picolinoyl)-1,3-diamino-2,2-dimethylpropane ##STR14##A solution of 2,2-dimethyl-1,3-propanediamine (5.00 g, 48.9 mmol) in DMF (500 mL) was treated with picolinic acid (12.6 g, 0.10 mol), 1-hydroxybenzotriazole hydrate (13.9 g, 0.10 mol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (19.7 g, 0.10 mol) and iPr2 NEt (17.9 mL, 0.10 mol) at room temperature. After 18 h, the reaction mixture was evaporated under vacuum and the residue purified by flash chromatography (75% EtOAc/hexanes, silica gel) to give 13.95 g (91%) the above named product as a clear solid. A fraction of this product (5.63 g) was recrystallized from ethyl acetate/hexane by slow evaporation to give 3.92 g of pure product as white needles. MS (ES+) m/e 313 [M+H+ ].
Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
| ______________________________________ |
| Tablets/Ingredients Per Tablet |
| ______________________________________ |
| 1. Active ingredient 0.5 mg |
| (Cpd of Form. I) |
| 2. Corn Starch 20 mg |
| 3. Alginic acid 20 mg |
| 4. Sodium alginate 20 mg |
| 5. Mg stearate 1.3 mg |
| ______________________________________ |
Procedure for tablets:
Step 1 Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender.
Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
Step 4 The wet granules are then dried in an oven at 140° F. (60°C) until dry.
Step 5 The dry granules are lubricated with ingredient No. 5.
Step 6 The lubricated granules are compressed on a suitable tablet press.
Parenteral Formulation
A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of Formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.
Hartmann, Michael, Bhatnagar, Pradip Kumar, Heerding, Dirk Andries, Callahan, James Francis, Hiebl, Johann, Kremminger, Peter, Rovenszky, Franz
| Patent | Priority | Assignee | Title |
| 7405210, | May 21 2003 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| 7884112, | Mar 08 2004 | Pyrrolopyridine-2-carboxylic acid hydrazides | |
| 8158622, | May 21 2003 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| Patent | Priority | Assignee | Title |
| 3917626, | |||
| 5360806, | Jul 23 1992 | Ishihara Sangyo Kaisha Ltd. | Amide compounds and their salts and pesticidal compositions containing them |
| 6030989, | Jan 13 1995 | SmithKline Beecham Corporation | Hemoregulatory compounds |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 07 1998 | ROVENSKY, FRANZ | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 07 1998 | KREMMINGER, PETER | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 07 1998 | HARTMANN, MICHAEL | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 07 1998 | ROVENSKY, FRANZ | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 07 1998 | KREMMINGER, PETER | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 07 1998 | HARTMANN, MICHAEL | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 20 1998 | HIEBL, JOHANN | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 20 1998 | HIEBL, JOHANN | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 28 1998 | HEERDING, DIRK ANDRIES | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 28 1998 | BHATNAGAR, PRADIP KUMAR | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 28 1998 | HEERDING, DIRK ANDRIES | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 28 1998 | BHATNAGAR, PRADIP KUMAR | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 29 1998 | CALLAHAN, JAMES FRANCIS | Nycomed Austria GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Oct 29 1998 | CALLAHAN, JAMES FRANCIS | SmithKline Beecham Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009677 | /0645 | |
| Dec 04 1998 | Nycomed Austria GmbH | (assignment on the face of the patent) | / | |||
| Dec 04 1998 | SmithKline Beecham Corporation | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Mar 10 2004 | REM: Maintenance Fee Reminder Mailed. |
| Aug 23 2004 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Aug 22 2003 | 4 years fee payment window open |
| Feb 22 2004 | 6 months grace period start (w surcharge) |
| Aug 22 2004 | patent expiry (for year 4) |
| Aug 22 2006 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 22 2007 | 8 years fee payment window open |
| Feb 22 2008 | 6 months grace period start (w surcharge) |
| Aug 22 2008 | patent expiry (for year 8) |
| Aug 22 2010 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 22 2011 | 12 years fee payment window open |
| Feb 22 2012 | 6 months grace period start (w surcharge) |
| Aug 22 2012 | patent expiry (for year 12) |
| Aug 22 2014 | 2 years to revive unintentionally abandoned end. (for year 12) |